Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma

Completed · Phase 2

Conditions studied: Brain and Central Nervous System Tumors

In brief

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors. PURPOSE: Phase II trial to study the effectiveness of radiolabeled monoclonal antibody in treating patients who have glioblastoma multiforme or anaplastic astrocytoma.

Key facts

Study ID

NCT00004017

Run by

Peregrine Pharmaceuticals

People needed

60

Starts

2000-02-01

Last updated by the study team

2009-02-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Carolina Neurosurgery and Spine Associates — Charlotte, North Carolina, United States
• Temple University — Philadelphia, Pennsylvania, United States
• Medical University of South Carolina — Charleston, South Carolina, United States
• Huntsman Cancer Institute — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.